Literature DB >> 12452395

Visceral sensitivity in gastroesophageal reflux.

Demetrios S Theodoropoulos1, Donna L Pecoraro, Richard F Lockey, H Worth Boyce, Samuel C Bukantz.   

Abstract

Symptomatic gastroesophageal reflux disease (GERD) is characterized by a wide spectrum of symptoms. The variance of GERD symptoms may be due to a decreased threshold for symptom elicitation/perception described as "visceral sensitivity." In this study GERD symptoms were scored for presence/frequency. The symptom score was weighted for the presence/frequency of typical reflux symptoms: heartburn, retrosternal pain, and regurgitation. The weighted GERD symptom score was used to assess symptom expansion and the hypothesis of GERD visceral sensitivity. One hundred five subjects with heartburn/retrosternal pain underwent esophageal pH studies. Subjects with abnormal esophageal pH studies reported more GERD-related symptoms, occurring more frequently, compared to subjects with normal esophageal pH studies. Symptom scores correlated with the number of reflux episodes but not with the length of time of mucosal exposure to acid. Therefore, aggregation of symptoms in gastroesophageal reflux is associated with frequent alternation between low and normal pH values in the distal esophagus.

Entities:  

Mesh:

Year:  2002        PMID: 12452395     DOI: 10.1023/a:1020528613756

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  26 in total

1.  Expression of the lung-specific thyroid transcription factor (TTF-1) within the tracheoesophageal fistula of embryo rats exposed to Adriamycin.

Authors:  D S Theodoropoulos; D K Ledford; R F Lockey
Journal:  J Pediatr Surg       Date:  2000-05       Impact factor: 2.545

2.  Primary eosinophilic esophagitis in children: successful treatment with oral corticosteroids.

Authors:  C A Liacouras; W J Wenner; K Brown; E Ruchelli
Journal:  J Pediatr Gastroenterol Nutr       Date:  1998-04       Impact factor: 2.839

3.  Human intestinal mast cells produce IL-5 in vitro upon IgE receptor cross-linking and in vivo in the course of intestinal inflammatory disease.

Authors:  A Lorentz; S Schwengberg; C Mierke; M P Manns; S C Bischoff
Journal:  Eur J Immunol       Date:  1999-05       Impact factor: 5.532

4.  Evaluation of T-lymphocytes in esophageal mucosal biopsies.

Authors:  H H Wang; M M Mangano; D A Antonioli
Journal:  Mod Pathol       Date:  1994-01       Impact factor: 7.842

5.  The pattern of esophageal acid exposure in gastroesophageal reflux disease influences the severity of the disease.

Authors:  G M Campos; J H Peters; T R DeMeester; S Oberg; P F Crookes; R J Mason
Journal:  Arch Surg       Date:  1999-08

6.  Allergic esophagitis in children: a clinicopathological entity.

Authors:  S V Walsh; D A Antonioli; H Goldman; V L Fox; A Bousvaros; A M Leichtner; G T Furuta
Journal:  Am J Surg Pathol       Date:  1999-04       Impact factor: 6.394

7.  The significance of intraepithelial eosinophils in the histologic diagnosis of gastroesophageal reflux.

Authors:  V Tummala; K W Barwick; S J Sontag; R Z Vlahcevic; R W McCallum
Journal:  Am J Clin Pathol       Date:  1987-01       Impact factor: 2.493

Review 8.  The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury.

Authors:  J A Koufman
Journal:  Laryngoscope       Date:  1991-04       Impact factor: 3.325

9.  Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD.

Authors:  K C Trimble; A Pryde; R C Heading
Journal:  Gut       Date:  1995-07       Impact factor: 23.059

10.  Characteristics and frequency of transient relaxations of the lower esophageal sphincter in patients with reflux esophagitis.

Authors:  R K Mittal; R W McCallum
Journal:  Gastroenterology       Date:  1988-09       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.